期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

来那度胺治疗多发性骨髓瘤异基因造血干细胞移植后cGVHD 1例并文献复习 被引量：4

下载PDF
导出
摘要 目的探讨来那度胺治疗多发性骨髓瘤异基因造血干细胞移植(allo-HSCT)后出现激素耐药慢性移植物抗宿主病(c GVHD)的临床效果。方法回顾1例接受来那度胺治疗的多发性骨髓瘤allo-HSCT后激素耐药c GVHD患者的临床资料,并复习相关文献。结果患者男,45岁,明确诊断为多发性骨髓瘤Ig D-λⅢA期(D-S)Ⅲ期(ISS),给予allo-HSCT治疗后出现c GVHD,并反复加重;给予糖皮质激素治疗,出现耐药;allo-HSCT后32个月复发,给予来那度胺及小剂量地塞米松(Rd方案)治疗,4个疗程后,c GVHD病情未再加重。患者目前应用Rd方案16个疗程,血象无明显抑制,血清蛋白电泳和免疫固定电泳均阴性,骨髓残留病监测未见异常浆细胞,STR为供者带型,疾病处于完全缓解状态。结论来那度胺治疗多发性骨髓瘤allo-HSCT后激素耐药c GVHD的效果较好,未见骨髓抑制等毒性作用。
作者 隋伟薇 邹德慧 徐燕 安刚 邓书会 赵耀中 邱录贵
机构地区 中国医学科学院血液病医院
出处 《山东医药》 CAS 北大核心 2016年第24期81-83,共3页 Shandong Medical Journal
基金 卫生部卫生行业科研专项项目(201202017) 天津市科技计划项目(12ZCDZSY17600)
关键词 多发性骨髓瘤 异基因造血干细胞移植 慢性移植物抗宿主病 来那度胺
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Dimopoulos MA,Delforge M,Hájek R,et al.Lenalidomide,melphalan,and prednisone,followed by lenalidomide maintenance,improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older:results of a randomized phase III trial[J].Haematologica,2013,98(5):784-788.
  • 2Stewart BL,Storer B,Storek J,et al.Duration of immunosuppressive treatment for chronic graft-versus-host disease[J].Blood,2004,104(2):3501-3506.
  • 3Wolff D,Gerbitz A,Ayuk F,et al.Consensus conference on clinical practice in chronic graft-versus-host disease(GVHD):firstline and topical treatment of chronic GVHD[J].Biol Blood Marrow Transplant,2010,16(12):1611-1628.
  • 4Wolff D,Schleuning M,von Harsdorf S,et al.Consensus conference on clinical practice in chronic GVHD:second-line treatment of chronic graft-versus-host disease[J].Biol Blood Marrow Transplant,2011,17(1):1-17.
  • 5Linhares YP,Pavletic S,Gale RP.Chronic GVHD:Where are we?Where do we want to be?Will immunomodulatory drugs help[J].Bone Marrow Transplant,2013,48(2):203-209.
  • 6Zhu YX,Braggio E,Shi CX,et al.Identification of cereblonbinding proteins and relationship with response and survival after IMiD s in multiple myeloma[J].Blood,2014,124(4):536-545.
  • 7Chang DH,Liu N,Klimek V,et al.Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide:therapeutic implications[J].Blood,2006,108(2):618-621.
  • 8Sun K,Welniak LA,Panoskaltsis-Mortari A,et al.Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib[J].Proc Natl Acad Sci U S A,2004,101(21):8120-8125.
  • 9Sun K,Wilkins DE,Anver MR,et al.Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease(GVHD):delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity[J].Blood,2005,106(9):3293-3299.
  • 10Weber DM,Chen C,Niesvizky R,et al.Multiple myeloma(009)study investigators.Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America[J].N Engl J Med,2007,357(21):2133-2142.

二级参考文献26

  • 1吴泰相,刘关键.隐蔽分组(分配隐藏)和盲法的概念、实施与报告[J].中国循证医学杂志,2007,7(3):222-225. 被引量：174
  • 2Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med, 2004, 351: 1860-1873.
  • 3Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc, 2005, 80: 1371-1382.
  • 4Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program, 2007: 317-323.
  • 5Hideshima T, Raje N, Richardson PG, et al. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag, 2008, 4(1): 129-136.
  • 6Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100: 3063- 3067.
  • 7Richardson P, Jagannath S, Hussein M, et al. A multicenter, singlearm,open-label study to evaluate the efficacy and safety of singleagent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood, 2005, 106: 449a.
  • 8Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 108: 3458-3464.
  • 9Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med, 2007, 357: 2133-2142.
  • 10Dimopoulos MA, Spencer A, Attal M, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2007, 357: 2123-2132.

共引文献20

同被引文献27

二级引证文献27

山东医药
2016年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部